Product Information
69004-1-Ig targets NeutraKine® IL-3 in Neutralization, ELISA, Blocking assay applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
Product name: HumanKine® recombinant human IL-3 protein Source: -derived, Tag: Sequence: Predict reactive species |
| Full Name | interleukin 3 (colony-stimulating factor, multiple) |
| Gene Symbol | IL-3 |
| Gene ID (NCBI) | 3562 |
| RRID | AB_2882922 |
| Conjugate | Unconjugated |
| Form | Lyophilized Powder |
| Purification Method | Protein G purification |
| UNIPROT ID | P08700 |
| Storage Buffer | Sterile PBS, pH 7.4. |
| Endotoxin | <0.1 EU/μg |
| Reconstitution | This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use. |
| Stability and Storage | Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products. |
Background Information
Interleukin-3 (IL-3) is a multilineage hematopoietic growth factor that promotes the proliferation, differentiation and survival of early multilineage hematopoietic progenitors. In particular, this cytokine plays a key role in stimulating the proliferation and survival of myeloid precursors. It is involved in a variety of cell activities such as cell growth, differentiation and apoptosis. This cytokine has been shown to also possess neurotrophic activity, and it may be associated with neurologic disorders (PMID: 24103757;2698876;2809196).
This antibody can be used to neutralize the bioactivity of IL-3.
Publications
What published studies show
The NeutraKine® IL-3 Mouse Monoclonal Antibody (3C11G7), catalog number 69004-1-Ig, has a total of 1 citation. It appears in the journal Cytotherapy (impact factor 4.5), in a 2025 study by Bryan Wang on an automated vertical wheel bioreactor integrated with process analytics for T-cell manufacturing. The associated research field is cell therapy/T-cell manufacturing, with the antibody used in a human blocking assay application.
| Species | Application | Title |
|---|---|---|
Cytotherapy Automated vertical wheel bioreactor integrated with process analytics for T-cell manufacturing. |
